Business
Adagio Medical Reports Fourth Quarter and Full Year 2024 Results
LAGUNA HILLS, Calif., March 31, 2025--Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024.
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"LAGUNA HILLS, Calif., March 31, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024.","length":291,"tagName":"p"},{"type":"text","content":"Recent Business Highlights:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total company revenue of $137 thousand in the fourth quarter of 2024, compared to $78 thousand in the fourth quarter of 2023. Full year revenue for 2024 was $0.6 million compared to $0.3 million in 2023.","length":212,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Surpassed 40% enrollment in the FULCRUM-VT pivotal study. The results of the study will be used to support FDA premarket approval (PMA) for Adagio’s VT Cryoablation System for endocardial ablation of scar-mediated ventricular tachycardia (VT). The study, which seeks to enroll 206 patients with ischemic and non-ischemic disease at 20 U.S. and Canadian centers, is on track for completion of patient enrollment in the second half of 2025.","length":438,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced focused realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption clinical trial activities and its new product design optimization program.","length":190,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported cash, cash equivalents, and short-term investments of $20.6 million as of December 31, 2024.","length":101,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":941,"olType":false},{"type":"text","content":""2024 was a pivotal year for Adagio, as we successfully commenced enrollment in our FULCRUM pivotal trial, securing the strategy to establish Adagio as a leading provider of treatments for ventricular tachycardia ("VT"). I am thrilled that the trial is enrolling ahead of expectations, bringing us even closer to providing a solution to this underserved patient population," said Todd Usen, Chief Executive Officer of Adagio. "With all of our resources today focused on two initiatives, the FULCRUM study and our product design optimization program, Adagio is well-poise...